Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype
NCT ID: NCT00808184
Last Updated: 2012-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
25 participants
INTERVENTIONAL
2010-04-30
2012-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To correlate pharmacokinetic parameters of raltegravir and midazolam with irinotecan (CPT-11) and its metabolite SN-38.
To correlate the genotype of UGT1A1 of patients receiving CPT-11 chemotherapy with irinotecan and raltegravir pharmacokinetic parameters.
To model pharmacokinetic and pharmacodynamic behaviour of CPT-11 in the study population.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To correlate the genotype of UGT1A1 of patients receiving CPT-11 chemotherapy with irinotecan and raltegravir pharmacokinetic parameters.
To model pharmacokinetic and pharmacodynamic behaviour of CPT-11 in the study population.
VI. Abstract of Research Proposal In no more than 300 words, describe concisely the specific aims, hypotheses, methodology and approach of the application, indicating where appropriate the application's importance to science or medicine. The abstract must be self-contained so that it can serve as a succinct and accurate description of the application when separated from it. Please use lay terms. If this not possible, the technical and medical terms should be explained in simple language. The pharmacokinetic parameters of raltegravir will correlate well with irinotecan (CPT-11) and its metabolite SN-38 and better than midazolam.
Raltegravir pharmacokinetic parameters can be used to predict the genotype of UGT1A1 of patients receiving CPT-11 chemotherapy with irinotecan. Patients who are prescribed the CPT-11 containing regimen FOLFIRI will be selected for the study.
Subjects will then undergo the raltegravir and midazolam test one day before the first dose of their chemotherapy. Pharmacokinetic sampling will occur for these 2 days. The raltegravir and midazolam test will be carried out under fasting conditions (minimum 10 hours). Between 8 to 9 am, one mg of midazolam will be administered intravenously over 30 seconds. At the same time, raltegravir 400 mg will be administered orally with water. Blood samples will be drawn at specified times for pharmacokinetic analysis from a heparinised butterfly needle in the opposite arm.
On the next day, FOLFIRI will be administered as follows:
CPT-11 at 180 mg/m2 in 250 mL Normal Saline over 90 min followed by Leucovorin at 400 mg/m2 in 250 mL Normal Saline over 2 hours followed by 5-Flourouracil 400 mg/m2 IV bolus followed by 5-Flourouracil 2400 mg/m2 over 46 hours. Premedications may be administered as per routine clinical practice. Blood will be taken at specified times for pharmacokinetic analysis. The pharmacokinetic parameters of the raltegravir and midazolam will be compared with the pharmacokinetic parameters of CPT-11 and its metabolite SN-38. Correlation analysis will be performed on the parameters to find the raltegravir or midazolam parameters which correlate best with the CPT-11 and SN-38 parameters. CPT-11 and raltegravir parameters will be correlated with UGT1A1 and other demographic information.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CPT-11
CPT-11, Raltegravir (Isentress®), Midazolam
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CPT-11, Raltegravir (Isentress®), Midazolam
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age above 21 years.
* Measurable or evaluable disease
* Karnofsky performance status \> 70%
* Life expectancy \> 3 months
* WBC \> 3.0 x 103/?l; ANC \> 1500/?l
* Hemoglobin \> 9.0 g/dl
* Platelets \> 100000/?l
* Creatinine \< 1.5 x ULN or calculated creatinine clearance \> 40 ml/min
* Total bilirubin \< 1.5 x ULN
* SGOT, SGPT \< 5 x ULN unless due to disease
Exclusion Criteria
* Radiation therapy within 4 weeks if \> 25% of bone marrow was irradiated.
* Have not received any medications that are known to be metabolised by UGT1A1 within 30 days of the first dose of CPT-11.
* Short gut syndrome or other causes of malabsorption.
* Colony stimulating factors within 2 weeks.
* Women of childbearing potential not practicing birth control. (Note: by means other than oral contraception)
* Pregnant women
* Severe peripheral neuropathy grade 2 or higher.
* Medical or psychiatric conditions which may impair the patient's ability to provide informed consent.
* Hypersensitivity to CPT-11, raltegravir or midazolam/other benzodiazepines.
* Rapidly progressive intracranial or spinal metastatic disease.
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National University Hospital, Singapore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boon Cher Goh, MRCP
Role: PRINCIPAL_INVESTIGATOR
National University Hospital, Singapore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National University Hospital
Singapore, , Singapore
Tan Tock Seng Hospital
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Atsumi R, Suzuki W, Hakusui H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica. 1991 Sep;21(9):1159-69. doi: 10.3109/00498259109039556.
Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE, Ratain MJ. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol. 1997 Apr;15(4):1502-10. doi: 10.1200/JCO.1997.15.4.1502.
Lee LS, Seng KY, Wang LZ, Yong WP, Hee KH, Soh TI, Wong A, Cheong PF, Soong R, Sapari NS, Soo R, Fan L, Lee SC, Goh BC. Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI. PLoS One. 2016 Jan 25;11(1):e0147681. doi: 10.1371/journal.pone.0147681. eCollection 2016.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PK01/16/08
Identifier Type: -
Identifier Source: org_study_id